PT-141 Injection Frequency Explained

PT-141 injection frequency means two different things depending on which product is in question. Vyleesi, the one FDA-approved form of bremelanotide, carries an actual labeled frequency limit. The lyophilized PT-141 vials sold for research use are a separate product with no such label, which puts their frequency in the hands of whoever designs the specific protocol. This reference explains both, and — more usefully — how frequency interacts with the reconstitution math that decides how long a research vial actually lasts. It is written for research and educational purposes only and is not medical advice.

Vyleesi has a labeled frequency; research vials don't

Vyleesi is a fixed-dose 1.75 mg bremelanotide autoinjector, approved by the FDA in 2019 for acquired, generalized hypoactive sexual desire disorder in premenopausal women. Its label sets real frequency limits: no more than one dose within 24 hours, and no more than 8 doses per month (FDA prescribing information, via DailyMed). That limit reflects the studied safety profile of one specific fixed-dose product administered as needed.

The lyophilized PT-141 research vials this site's calculator is built around are a different product entirely — reconstituted with bacteriostatic water rather than shipped as a pre-filled autoinjector, and never reviewed for an approved indication. No regulatory body has set a frequency for that product, so any PT-141 injection frequency attached to a research vial is a protocol detail, not a label requirement. Carrying Vyleesi's 8-doses-per-month limit over to a research vial assumes the two products are interchangeable, and they aren't — see the PT-141 dosage calculator guide for how the two products' dosing also diverges on concentration and vial size.

What frequency actually controls

Frequency answers one question: how many times per period does a draw come out of the vial. It does not answer a separate question: what is the concentration of what's in the vial. That second question is fixed the moment bacteriostatic water is added:

Concentration = vial mass (mcg) ÷ water added (mL)

A vial reconstituted to a given concentration stays at that concentration through every draw, whether a protocol calls for one draw a day or one draw every few days. Frequency and concentration are independent variables that happen to combine into a third, more practical number: how many days a single vial will actually cover.

Worked example: vial life at two frequencies

Take a 10 mg PT-141 vial reconstituted with 2 mL of bacteriostatic water, at a 1,000 mcg (1 mg) target dose per draw — the same reference setup used in the PT-141 dosage calculator guide.

Step 1 — convert vial mass to mcg. 10 mg = 10,000 mcg (1 mg = 1,000 mcg).

Step 2 — concentration. 10,000 mcg ÷ 2 mL = 5,000 mcg/mL.

Step 3 — mcg per unit. On a U-100 insulin syringe, 1 mL equals 100 units, so 5,000 mcg/mL ÷ 100 = 50 mcg per unit.

Step 4 — syringe units per draw. 1,000 mcg ÷ 50 mcg per unit = 20 units.

Step 5 — doses per vial. 10,000 mcg ÷ 1,000 mcg = 10 doses. This number depends only on vial mass and dose size — the water volume chosen in Step 2 doesn't change it.

Step 6 — vial life by frequency. At once daily, 10 doses run 10 days, or about 1.4 weeks. At every other day, the same 10 doses stretch to 10 × 2 = 20 days, or about 2.9 weeks. Neither frequency is presented here as a recommendation — they're two illustrative points showing how the same vial and dose produce very different vial-life numbers depending on how often it's drawn.

A 5 mg vial in the same 2 mL of water follows the identical formula at a lower total. 5,000 mcg ÷ 2 mL = 2,500 mcg/mL, or 25 mcg per unit, so the same 1,000 mcg dose now takes 1,000 ÷ 25 = 40 units — a larger draw from a lower-concentration vial. Doses per vial drop to 5,000 ÷ 1,000 = 5. At once daily that's 5 days (about 0.7 weeks); at every other day, 10 days (about 1.4 weeks).

Vial size	Water added	Concentration	1,000 mcg dose (units)	Doses per vial	Vial life — once daily	Vial life — every other day
5 mg	2 mL	2,500 mcg/mL	40 units	5	5 days (~0.7 weeks)	10 days (~1.4 weeks)
10 mg	2 mL	5,000 mcg/mL	20 units	10	10 days (~1.4 weeks)	20 days (~2.9 weeks)

Frequency and dose size are separate decisions

It's easy to assume a higher PT-141 injection frequency automatically means a smaller per-draw dose, since that pattern shows up in some protocols. The arithmetic doesn't require it. A protocol can hold the dose steady and simply draw from the vial more often — which draws the vial down faster and shortens vial life — or it can lower the dose to stretch the same vial across more frequent draws. Frequency, dose size, and vial life are three separate numbers connected by the doses-per-vial formula above; changing one doesn't automatically change another unless the protocol is designed that way.

Why research protocols on frequency disagree

Outside Vyleesi's approved label, there's no single standard to converge around, so published and self-reported research protocols for reconstituted PT-141 describe a range of schedules rather than one number. Some describe daily draws; others space them out further. This guide does not recommend a frequency or take a position on which protocol is better — that's a research design question outside the scope of a reconstitution reference, and outside what a peptide calculator can tell you. What the math above can tell you is how any given frequency plays out against a specific vial size, water volume, and dose once a protocol has settled on one.

Keeping frequency and concentration from drifting apart

A frequency-based vial-life estimate is only accurate if the concentration behind it hasn't changed. Track the date a vial was reconstituted, not just when it was opened — see how to store reconstituted peptides for the general reasoning. If a vial that should supply 10 doses at 5,000 mcg/mL runs out sooner than the frequency and dose size predict, the concentration used in the original calculation is the more likely source of the mismatch, not the compound itself.

Common mistakes

• Applying Vyleesi's 8-doses-per-month limit to a research vial. That limit belongs to one specific approved autoinjector product, not to a reconstituted vial at an arbitrary concentration.
• Assuming frequency changes concentration. It doesn't. Concentration is fixed at reconstitution; frequency only affects how fast the vial's total mcg gets drawn down.
• Confusing mg and mcg when estimating vial life. PT-141 vials are labeled in milligrams, but doses are usually described in micrograms — a 10 mg vial is 10,000 mcg, not 10.
• Reusing a vial-life estimate after changing the water volume or dose. The 10-day and 20-day figures above only hold at 5,000 mcg/mL and a 1,000 mcg dose. Change either input and the vial-life number changes with it.

Use the calculator

Enter a PT-141 vial size, bacteriostatic water volume, and target dose into the free peptide calculator to get the exact concentration, draw volume, and syringe units, then apply an intended frequency to the doses-per-vial figure to estimate vial life. For the full reconstitution walkthrough and the Vyleesi comparison in more detail, see the PT-141 dosage calculator guide.